Skip to main content

Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses Cover

.blurhash-client-img { display: none !important; }

Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses

Acta Pharmaceutica

Volume 60 (2010): Issue 4 (December 2010)

By: Septimiu Bucurescu

Open Access

|Dec 2010

Abstract

Future cancer therapies will be molecular cures. They will correct, block or destroy cancer cells by targeting molecular changes that lead to carcinogenesis. Destroying cancer cells can be done using oncolytic viruses. By blocking antibody mediated neutralization of oncolytic viruses, Herpes simplex virus type 1 glycoproteins E and I could be used in the adjuvant treatment of cancer for improving the chances of oncolytic viruses to kill cancer cells in vivo.

References

B. Stewart and P. Kleihues, World Cancer Report, IARC Press, Lyon 2003.
Search in Google Scholar
National Cancer Institute, Methods for Treatment and Their Side Effectshttp://www.nci.nih.gov/cancertopics/wyntk/overview/page15
Search in Google Scholar
T. W. Fischer, M. A. Zmijewski, B. Zbytek, T. W. Sweatman, R. M. Slominski, J. Wortsman and A. Slominski, Oncostatic effects of the indole melatonin and expression of its cytosolic and nuclear receptors in cultured human melanoma cell lines, Int. J. Oncol. 29 (2006) 665-672.
Search in Google Scholar
H. Brenner, Long-term survival rates of cancer patients achieved by the end of the 20^th century: a period analysis, Lancet 360 (2001) 1131-1135; DOI: 10.1054/bjoc.2001.1905.10.1054/bjoc.2001.1905
Search in Google Scholar
J. L. Gajewski and R. E. Champlin, Blood Stem Cell and Marrow Transplantation, in Cancer Treatment (Ed. C. M. Haskell and J. S. Berek), W. B. Saunders, Philadelphia 2001, pp. 276-295.
Search in Google Scholar
S. Bucurescu, Introduction to Pharmaceutical Medicine, RG Fischer Verlag, Frankfurt am Main 2008, pp. 118-122.
Search in Google Scholar
N. dePace, Sulla scomparsa di un enorme cancro vegetante del collo dell'utero senza cura chirurgica, Ginecologia 9 (1912) 82-89.
Search in Google Scholar
E. Kelly and S. J. Russel, History of oncolytic viruses: genesis to genetic engineering, Mol. Ther. 15 (2007) 651-659; DOI: 10.1038/sj.mt.6300108.10.1038/sj.mt.6300108
Search in Google Scholar
T-C. Liu and D. Kirn, Gene therapy progress and prospects cancer: oncolytic viruses, Gene Ther. 15 (2008) 877-884; DOI: 10.1038/gt.2008.72.10.1038/gt.2008.72
Search in Google Scholar
K. Garber, China approves world's first oncolytic virus therapy for cancer treatment, J. Natl. Cancer I. 98 (2006) 298-300; DOI: 10.1093/jnci/djj111.10.1093/jnci/djj111
Search in Google Scholar
S. Meerani and Y. Yao, Oncolytic viruses in cancer therapy, Eur. J. Sci. Res. 40 (2010) 156-171.
Search in Google Scholar
Z. S. Guo, S. H. Thorne and D. L. Bartlett, Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses, Biochim. Biophys. Acta 1785 (2008) 217-231; DOI: 10.1016/j.bbcam.2008.02.001.
Search in Google Scholar
S. Naik and S. J. Russel, Engineering oncolytic viruses to exploit tumor specific defects in innate immune signalling pathways, Expert Opin. Biol Th. 9 (2009) 1163-1176; DOI: 10.1517/14712590903170653.10.1517/14712590903170653
Search in Google Scholar
R. Diasio and A. F. LoBuglio, Immunomodulators: Immunosuppressive Agents and Immunostimulants, in Goodman & Gilman's The Pharmacological Basis of Therapeutics (Ed. J. G. Hardman, A. Goodman Gilman and L. E. Limbird), McGraw-Hill, New York, 2006, pp. 1291-1308.
Search in Google Scholar
D. J. McGeoch, J. A. Dolan, S. Donald and F. J. Rixon, Sequence determination and genetic content of the short unique region in the genome of herpes simplex virus type 1, J. Mol. Biol. 181 (1985) 1-13; DOI: 10.1016/0022-2836(85)90320-1.10.1016/0022-2836(85)90320-1
Search in Google Scholar
H. M. Friedman, Immune evasion by herpes simplex virus type 1, strategies for virus survival, Trans. Am. Clin. Climatol Assoc. 114 (2008) 103-112.
Search in Google Scholar
D. Westmoreland and J. F. Watkins, The IgG receptor induced by herpes simplex virus: studies using radioiodinated IgG, J. Gen. Virol. 24 (1974) 167-178; DOI: 10.1099/0022-1317-24-1-167.10.1099/0022-1317-24-1-167
Search in Google Scholar
J. P. G. Sissons, Herpes Viruses (Excluding Epstein-Barr Virus), in Oxford Textbook of Medicine (Eds. D. A. Warell, T. M. Cox, J. D. Firth and E. J. Benz), Oxford University Press, New York 2003, pp. 327-341.
Search in Google Scholar
J. Sambrook and D. Russel D, The Condensed Protocols from Molecular Cloning: a Laboratory Manual, CSHL Press, Cold Spring Harbor 2006.10.1101/pdb.prot3919
Search in Google Scholar
J. Vieira and J. Messing, The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers, Gene 19 (1982) 259-268; DOI 10.1016/0378-1119(82)90015-4.10.1016/0378-1119(82)90015-4
Search in Google Scholar
F. Baneyx, Recombinant protein expression in Escherichia coli, Curr. Opin. Biotechnol. 10 (1999) 411-421; DOI: 10.1016/50958-1669(99)00003-8.
Search in Google Scholar
J. Weiss, Handbook of Ion Chromatography, Wiley-VCH, Weinheim 2004, pp. 279-349.10.1002/9783527619610
Search in Google Scholar
J. F. Watkins, Adsorption of sensitized sheep erythrocytes to HeLa cells infected with herpes simplex virus, Nature 202 (1964) 1364-1365; DOI: 10.1038/2021364a0.10.1038/2021364a0
Search in Google Scholar
T. Van Dyke and T. Jacks, Cancer modeling in the modern era: progress and challenges, Cell 108 (2002) 135-144; DOI: 10.1016/S0092-8674(02)00621-9.10.1016/S0092-8674(02)00621-9
Search in Google Scholar
D. Cervantes-Garcia, R. Ortiz-Lopez, N. Mayek-Perez and A. Rojas-Martinez, Oncolytic virotherapy, Ann. Hepatol. 7 (2008) 34-45.10.1016/S1665-2681(19)31885-X
Search in Google Scholar
N. Ting, Dose Finding in Drug Development, Springer, New York 2006, pp. 304-310.10.1007/0-387-33706-7
Search in Google Scholar
R. C. Rowe, P. J. Sheskey and M. E Quinn, Handbook of Pharmaceutical Excipients, Pharmaceutical Press, Chicago 2009, pp. 69-301.
Search in Google Scholar
International Conference on Harmonisation, Harmonised Tripartite Guideline, Timing of Non-clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals, ICH, Geneve 1998; http://www.ema.europa.eu/ema/index.jsp?cure=pages/regulation/general/general_content_000430.jsp&murl=menus/regulations/regulation.jsp&mid=WC0b01ac058002992&jsenabled=true
Search in Google Scholar
International Conference on Harmonisation Harmonised Tripartite Guideline, The Principles of Good Clinical Practice, ICH, Geneve 1996; http://www.ich.org/LOB/media/MEDIA482.pdf
Search in Google Scholar

Articles in this issue

DOI: https://doi.org/10.2478/v10007-010-0039-2 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075

Journal RSS Feed

Language: English

Page range: 407 - 413

Published on: Dec 17, 2010

Published by: Croatian Pharmaceutical Society

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

cancer therapies,

Herpes simplex virus type 1 glycoproteins E and I,

antibody mediated neutralization of oncolytic viruses

Related subjects:

Pharmacy, other

© 2010 Septimiu Bucurescu, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons License.

Volume 60 (2010): Issue 4 (December 2010)